| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2011 | EP2312946A1 Pyrimidine derivatives for treatment of alzheimer's disease |
| 04/27/2011 | EP2312945A1 Purine derivatives for treatment of alzheimer's disease |
| 04/27/2011 | EP2102199B1 Antibacterial polycyclic urea compounds |
| 04/27/2011 | EP2090575B1 Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives |
| 04/27/2011 | EP2054057B1 Combination andolast/glucocorticoids |
| 04/27/2011 | EP2039367B1 Prophylactic/therapeutic agent for neurodegenerative disease |
| 04/27/2011 | EP2029566B1 Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity |
| 04/27/2011 | EP2007352B1 Treatment of psychiatric patients with sleep disturbances and/or excessive daytime sleepiness with paliperidone |
| 04/27/2011 | EP2001862B1 Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid |
| 04/27/2011 | EP1976520B1 Kit comprising an osmotic laxative and a stimulant laxative for preparing the colon for virtual colonoscopy |
| 04/27/2011 | EP1968967B1 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators |
| 04/27/2011 | EP1959938B1 Matrix-controlled transdermal system comprising salts of ace inhibitor dicarboxylic acids |
| 04/27/2011 | EP1951724B1 FUSED BICYCLIC mTOR INHIBITORS |
| 04/27/2011 | EP1942985B1 Methods for reducing blood pressure |
| 04/27/2011 | EP1937245B1 Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients |
| 04/27/2011 | EP1891035B1 Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs |
| 04/27/2011 | EP1879598B1 Adjuvant comprising oligonucleotide and non toxic lps |
| 04/27/2011 | EP1844026B1 Morpholines as 5ht2c agonists |
| 04/27/2011 | EP1841426B1 Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease |
| 04/27/2011 | EP1833967B1 Conserved hbv and hcv sequences useful for gene silencing |
| 04/27/2011 | EP1824832B1 Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
| 04/27/2011 | EP1812112B1 Benzodiazepine derivatives as ROCK kinases inhibitors |
| 04/27/2011 | EP1809330B1 Compositions for reducing toxicity of cisplatin, carboplatin, and oxaliplatin |
| 04/27/2011 | EP1793671B1 Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| 04/27/2011 | EP1792985B1 Cell fusion promoter and utilization of the same |
| 04/27/2011 | EP1735303B1 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof |
| 04/27/2011 | EP1709052B1 Derivatives of 1,4-diazabicyclo 3.2.1octanecarboxamide, preparation method thereof and use of same in therapeutics |
| 04/27/2011 | EP1689723B1 Reference standard for characterization of rosuvastatin |
| 04/27/2011 | EP1670444B1 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 04/27/2011 | EP1663242B1 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| 04/27/2011 | EP1554315B1 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 04/27/2011 | EP1521746B1 Quinazolinone modulators of nuclear receptors |
| 04/27/2011 | EP1477175B1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| 04/27/2011 | EP1467967B1 Compounds for modulating cell proliferation |
| 04/27/2011 | EP1439175B1 Pyrimidine compound and medicinal composition thereof |
| 04/27/2011 | EP1419175B1 Replikin peptides and uses thereof |
| 04/27/2011 | EP1383463B1 Fused thiophene compounds and use thereof in the treatment of chronic pain |
| 04/27/2011 | EP1317470B1 Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate tumor therapy |
| 04/27/2011 | EP1317304B1 Slow release pharmaceutical preparation and method of administering same |
| 04/27/2011 | EP1307194B2 Fentanyl composition for nasal administration |
| 04/27/2011 | EP1303541B1 Compositions containing metronidazole |
| 04/27/2011 | EP1257292B1 Use of il-18 inhibitors |
| 04/27/2011 | EP1253966B1 Substances and agents for positively influencing collagen |
| 04/27/2011 | EP1197218B1 Algae protein polysaccharide extraction and use thereof |
| 04/27/2011 | EP1177796B1 Medicament for prevention or therapeutic treatment of liver disease |
| 04/27/2011 | EP1118660B1 Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme |
| 04/27/2011 | EP0934307B1 Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| 04/27/2011 | CN1993346B Thiophene compound |
| 04/27/2011 | CN1985891B Compound Chinese medicine preparation with liver protecting function and its preparing process |
| 04/27/2011 | CN1981810B Danshen component, preparation, making method and usage |
| 04/27/2011 | CN1970556B 1-furfuryl-3-substituted Indolinyl-2-one derivative, its preparation method and uses |
| 04/27/2011 | CN1946390B Anti-wrinkle agent |
| 04/27/2011 | CN1919248B Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease |
| 04/27/2011 | CN1919244B Chinese traditional medicine for treating cardiovascular disease |
| 04/27/2011 | CN1893925B In vivo targeting of dendritic cells |
| 04/27/2011 | CN1872079B Drop pills for treating cardiovascular diseases and cerebrovascular disease, and preparation method |
| 04/27/2011 | CN1738621B Physically and chemically stable nicotine-containing particulate material |
| 04/27/2011 | CN1706378B Composition for treating inflammation which contains zinc pyrrolidonecarboxylate |
| 04/27/2011 | CN1620302B Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12 |
| 04/27/2011 | CN1556706B Thieno [1,3] oxazin-4-ones with lipase inhibiting activity |
| 04/27/2011 | CN102037123A Compositions and use of epas1 inhibitors |
| 04/27/2011 | CN102037058A Docetaxel polymer derivative, method for producing same and use of same |
| 04/27/2011 | CN102036997A Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| 04/27/2011 | CN102036996A Bridged heterocycles as HIV integrase inhibitors |
| 04/27/2011 | CN102036995A Triazine compounds as P13 kinase and mTOR inhibitors |
| 04/27/2011 | CN102036993A Nalmefene di-ester prodrugs |
| 04/27/2011 | CN102036991A GPR119 receptor agonists |
| 04/27/2011 | CN102036990A Novel tyrosine kinase inhibitors |
| 04/27/2011 | CN102036989A Polysubstituted derivatives of 6-heteroaryl-imidazo[l,2-a] pyridines, and preparation and therapeutic use thereof |
| 04/27/2011 | CN102036988A Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[l,2-a] pyridines, and preparation and therapeutic use thereof |
| 04/27/2011 | CN102036987A Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[l,2- a] pyridines, and preparation and therapeutic use thereof |
| 04/27/2011 | CN102036985A 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| 04/27/2011 | CN102036984A Novel compounds as cannabinoid receptor ligands |
| 04/27/2011 | CN102036981A Substituted 4-hydroxypyrimidine-5-carboxamides |
| 04/27/2011 | CN102036980A Substituted thiophenecarboxamides as IKK-beta serine-, threonine-protein kinase inhibitors |
| 04/27/2011 | CN102036979A Inhibitors of IKK-beta serine-theronine protein kinase |
| 04/27/2011 | CN102036978A Novel thiophenediamine derivative having urea structure |
| 04/27/2011 | CN102036976A Modulators of dopamine neurotransmission |
| 04/27/2011 | CN102036972A Treatment of duchenne muscular dystrophy |
| 04/27/2011 | CN102036971A 3- or 4-substituted piperidine compounds |
| 04/27/2011 | CN102036967A Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists |
| 04/27/2011 | CN102036964A Tetrahydroisoquinolines as antimalarial agents |
| 04/27/2011 | CN102036963A Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| 04/27/2011 | CN102036962A Combined use of angiogenesis inhibitor and taxane |
| 04/27/2011 | CN102036961A Pyridines and pyrazines as inhibitors of PI3K |
| 04/27/2011 | CN102036959A Polysubstituted 2-aryl-6-phenyl-imidazo[l,2-a] pyridine derivatives, and preparation and therapeutic use thereof |
| 04/27/2011 | CN102036956A Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| 04/27/2011 | CN102036955A Hydroxamate-based inhibitors of deacetylases b |
| 04/27/2011 | CN102036953A Arylsulfonamide-based matrix metalloprotease inhibitors |
| 04/27/2011 | CN102036952A Bis-aryl compounds for use as medicaments |
| 04/27/2011 | CN102036946A Co-crystals of duloxetine and Cox-inhibitors for the treatment of pain |
| 04/27/2011 | CN102036936A Novel [F-18]-labelled l-glutamic acid and l-glutamine derivatives (II), use thereof and method for their production |
| 04/27/2011 | CN102036714A Anhydrous and hydrate forms of crystalline 2- ( (2s, 3r, 4e, 6e, 1oe, 12s) -13- (4-fluorophenoxy) -2,3, 12- (trihydroxytrideca-4, 6, 10-trien-8-ynyl) oxy) acetic acid |
| 04/27/2011 | CN102036713A Methods relating to breathing disorders |
| 04/27/2011 | CN102036686A Water-containing composition |
| 04/27/2011 | CN102036682A Set of antiangiogenic molecules and use thereof |
| 04/27/2011 | CN102036672A Antitumoral terpenoid pharmaceutical composition 'ABISILIN' exhibiting angiogenesis-inhibiting action |
| 04/27/2011 | CN102036670A Method for decreasing inflammation and oxidative stress in mammals |
| 04/27/2011 | CN102036669A Pharmaceutical composition for the treatment of premature ejaculation |
| 04/27/2011 | CN102036668A Pest control compositions and methods |